Powered by
-Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RAR Agonist in Combination with Daratumumab

CAMBRIDGE, Mass. - Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that it has entered into a clinical supply agreement with Janssen Research and Development, LLC.

Under the agreement, Janssen will supply daratumumab for a recently added combination dosing cohort in Syros' ongoing Phase 2 clinical trial of SY-1425, a first-in-class selective retinoic acid receptor a

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox